Table 1.
Clinical and pathologic variables associated with time to recurrence (TTR) in early stage BC
| Parameter | No. Of Patients (%) | HR (95% cl)α | P-value |
|---|---|---|---|
| Stage: | |||
| 1 | 308 (30) | 1(reference) | |
| 2 | 722 (70 | 1.82 (1.34, 2.48) | 0.00 |
| Black's Nuclear Grade: | |||
| 1 | 99 (10) | 1 | |
| 2 | 541 (53) | 0.87 (0.66, 1.14) | 0.29 |
| 3 | 347 (37) | 1.90 (0.68, 1.64 | 0.81 |
| Hormone receptor status: | |||
| ER− and PR− | 246 (24) | 1 | |
| ER+ or PR+ | 750 (73) | 0.76 (0.58, 1.00) | 0.05 |
| NAb | 34 (3) | ||
| Age: | |||
| ≤50 | 436 (42) | 1 | |
| >50 | 594 (58) | 0.57 (0.45, 0.73) | 0.00 |
| Treatment: | |||
| None | 231 (23) | 1 | |
| Chemotherapy only | 333 (32) | 1.27 (0.93, 1.73) | 0.14 |
| Endocrine therapy only | 259 (25) | 0.68 (0.46, 0.99) | 0.04 |
| Chemotherapy + Endocrine therapy | 202 (20) | 0.73 (0.48, 1.11) | 0.14 |
| NAb | 5 (---) | ||
| BMI: | |||
| Underweight/normal | 429 (42) | 1 | |
| Overweight | 297 (29) | 1.05 (0.78, 1.40) | 0.71 |
| Obese | 279 (27) | 0.91 (0.66, 1.25) | 0.57 |
| NA | 25 (2) | ||
| Race: | |||
| Caucasian | 739 (72) | 1 | |
| African-American | 141 (14) | 1.17 (0.83, 1.67) | 0.37 |
| Hispanic | 117 (11) | 1.08 (0.72, 1.60) | 0.72 |
| NA | 33 (3) | ||
b
Abbreviations used: NA: not available; ER:estrogen receptor; PR: Progesterone receptor; BM: body mass index; HR: hazard ratio; Cl: confidence interval